[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-337112-105":59,"doc-detail-337112-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","selective-delivery-of-g-quadruplex-ligand-in-glioma-cell-lines-the-power-of-cyclic-rgd-peptide","Selective delivery of G-quadruplex ligand in glioma cell lines - the power of cyclic-RGD peptide","","Selective delivery of G-quadruplex ligands is pursued as a strategy to improve anticancer selectivity, since many G4-targeting small molecules show high cytotoxicity but insufficient discrimination between cancerous and healthy cells. A cyclic arginylglycyl-aspartic acid peptide was conjugated to a naphthalene diimide ligand designed to stabilize DNA G-quadruplexes, enabling preferential targeting of glioma cells overexpressing RGDbinding integrin receptors. Confocal microscopy and cell toxicity assays indicate improved selective uptake and efficacy without impairing the NDI’s G4-interaction ability.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/selective-delivery-of-g-quadruplex-ligand-in-glioma-cell-lines-the-power-of-cyclic-rgd-peptide/337112/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/selective-delivery-of-g-quadruplex-ligand-in-glioma-cell-lines-the-power-of-cyclic-rgd-peptide/337112.png","ImageObject",300,407,{"name":92,"@type":93},"Clementine","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is selectivity a key challenge for G-quadruplex ligands?","Question",{"text":112,"@type":113},"Many G4-targeting cytotoxic molecules act without sufficient selectivity, leading to systemic distribution, off-target interactions, and undesirable side effects in healthy cells.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What conjugate strategy was used to improve glioma targeting?",{"text":117,"@type":113},"The study conjugated a cyclic arginylglycyl-aspartic acid (cRGD) peptide to a naphthalene diimide ligand previously reported as a strong stabilizer of DNA G-quadruplexes, aiming to target RGDbinding integrin-overexpressing glioma cells.",{"name":119,"@type":110,"acceptedAnswer":120},"How did the researchers evaluate the new conjugate’s performance?",{"text":121,"@type":113},"Confocal microscopy and cell toxicity assays were used to demonstrate improved selective cellular absorption and enhanced efficacy, while maintaining the NDI’s ability to interact with the G4 target.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},337112,1790875378,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},1374391974564,"https://ap-avatar.wpscdn.com/avatar/14000253aa45c000a9e?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779874745381141002","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nSelective delivery of G-quadruplex ligand in glioma cell lines: the power of cyclic-RGD peptide  \nValentina Pirota1,4, Giovanni Bisbano2,4, Amanda Oldani3, Eric Bernardi2, Massimo Serra2􀀍, Mayra Paolillo2􀀍 & Filippo Doria1􀀍  \nCompounds targeting non-canonical secondary structures of nucleic acids, known as G-quadruplexes, are highly cytotoxic, both for cancer and healthy cells, because of their action mechanism’s lack of appropriate selectivity. The targeted delivery of cytotoxic molecules to cancer cells is a valuable strategy to expand the repertoire of potential drugs, especially for cancer types for which new therapeutic tools are urgently needed, like glioblastoma. In this work, we conjugated a cyclic arginylglycyl-aspartic acid peptide to a naphthalene diimide, previously described as a highly performing stabilizing ligand for DNA G-quadruplexes, to specifically target glioma cells overexpressing RGDbinding integrin receptors. Our results, including confocal microscopy and cell toxicity assays, demonstrated improved efficacy and selective cellular absorption of the new conjugate without affecting the NDI’s ability to interact with the G4 target.  \nThe selective targeting by small molecules of non-canonical secondary structures of nucleic acids known as G-quadruplexes (G4s) is recognized as a cutting-edge and robust strategy against different pathologies1–5. G4s are highly structured conformations within key genomic regions, such as telomers, gene promoters, and untranslated regions6. Because of their acknowledged involvement in essential biological processes along with the countless experimental data proving their existence in living cells, they gained significant importance in medicinal chemistry7,8. Among all, over the years, many efforts have been made to strategically manipulate the folding of G4s with the ambitious aim of pioneering groundbreaking anticancer therapies1,9. Nevertheless, among the numerous organic small molecules designed and synthesized to selectively recognize the G4s of interest, only some of these have reached the pre-clinical phase10. Indeed, despite the promising biological outcomes as potential anticancer drugs, many of these compounds lack the specificity needed to differentiate between cancerous and normal cells. This lack of specificity leads to systemic distribution, increasing the risk of off-target interactions and undesirable side effects. Significant progress has been made in the selective delivery of G4-ligands to cancer cells11, 12, however, ongoing research and innovative strategies are crucial to overcoming the remaining challenges and improving treatment outcomes. In this context, we have undertaken a proofof-concept study to enhance the cellular uptake of a tetrasubstituted naphthalene diimide (NDI-1 in Fig. 1), widely recognized as a highly effective G4-stabilizing ligand13, 14, by a covalent linkage with a cyclic arginylglycyl-aspartic acid peptide (1a-cRGD in Fig. 1)15, 16. NDI-1 previously demonstrated significant stabilization of telomeric G4 structure over duplex DNA, exhibiting a good telomerase inhibition14. However, it did not show a marked preference for breast and lung cancer cell lines over normal human fibroblast with selective indexes equal to 2.8 (IC50WI38/IC50MCF7) and 10.2 (IC50WI38/IC50A549) respectively14. This behavior is consistent with that observed for many G4 ligands17as well as NDIs13, which, despite their potential as anticancer agents, frequently exhibit limited cell selectivity and significant cytotoxicity toward healthy cells. The RGD (Arg-Gly-Asp) tripletis a well-known integrin-binding sequence specifically recognized by ανβ3, ανβ5, and α5β1 integrins, which are overexpressed on the surface of different cancer cells and angiogenic blood vessels and minimally expressed in normal cells18.  \nThe conjugation of a potent G-quadruplex ligand like NDI-1 with RGD-based cyclopenta","cbCaigenEvxOiSRP","https://ap.wps.com/l/cbCaigenEvxOiSRP","pdf",4601721,"English","# Selective delivery concept\n## G-quadruplexes (G4s) as therapeutic targets\n## Limitations of existing G4 ligands and need for selectivity\n## Proof-of-concept conjugate design (NDI-1 and cyclic cRGD)\n## RGD-integrin targeting rationale\n## Expected integrin-mediated internalization and goals for glioblastoma","[{\"question\":\"Why is selectivity a key challenge for G-quadruplex ligands?\",\"answer\":\"Many G4-targeting cytotoxic molecules act without sufficient selectivity, leading to systemic distribution, off-target interactions, and undesirable side effects in healthy cells.\"},{\"question\":\"What conjugate strategy was used to improve glioma targeting?\",\"answer\":\"The study conjugated a cyclic arginylglycyl-aspartic acid (cRGD) peptide to a naphthalene diimide ligand previously reported as a strong stabilizer of DNA G-quadruplexes, aiming to target RGDbinding integrin-overexpressing glioma cells.\"},{\"question\":\"How did the researchers evaluate the new conjugate’s performance?\",\"answer\":\"Confocal microscopy and cell toxicity assays were used to demonstrate improved selective cellular absorption and enhanced efficacy, while maintaining the NDI’s ability to interact with the G4 target.\"}]","Selective delivery of G-quadruplex ligand in glioma cell lines - the power of cyclic-RGD peptide | PDF",1790017746,25,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ceffca78beeebbb7f2fdeebb8729b650.webp",983,1291,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/941359343037bb55d7550ecb18c457e3.webp",982,1290,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d13c7d51e503baeb8415bf8510e2fdfa.webp",981,1289,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bc813f481df0ed832e5d4e5820110809.webp",980,1287]